Bid mediates apoptotic synergy between tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and DNA damage
V Courtney Broaddus1, Tobias B Dansen, Keith S Abayasiriwardana
1Lung Biology Center, San Francisco General Hospital, University of California San Francisco, San Francisco, California 94143-0854, USA. sfcourt@itsa.ucsf.edu
Abstract:
The death ligand, TRAIL (tumor necrosis factor-related apoptosis-inducing ligand), has shown great promise for inducing apoptosis selectively in tumors. Although many tumor cells are resistant to TRAIL-induced apoptosis alone, they can often be sensitized by co-treatment with DNA-damaging agents such as etoposide. However, the molecular mechanism underlying this therapeutically important synergy is unknown. We explored the mechanism mediating TRAIL-DNA damage apoptotic synergy in human mesothelioma cells, a tumor type particularly refractory to existing therapies. We show that Bid, a cytoplasmic Bcl-2 homology domain 3-containing protein activated by caspase 8 in response to TRAIL ligation, is essential for TRAIL-etoposide apo-ptotic synergy and, furthermore, that exposure to DNA damage primes cells to induction of apoptosis by otherwise sublethal levels of activated Bid. Finally, we show that the extensive caspase 8 cleavage seen during TRAIL-etoposide synergy is a consequence and not a cause of the apoptotic cascade activated downstream of Bid. These data indicate that TRAIL-etoposide apoptotic synergy arises because DNA damage increases the inherent sensitivity of cells to levels of TRAIL-activated Bid that would otherwise be insufficient for apoptosis. Such studies indicate how the adroit combination of differing proapoptotic and sublethal signals can provide an effective strategy for treating refractory tumors.
Insights
Combining TRAIL (tumor necrosis factor-related apoptosis-inducing ligand) with DNA-damaging agents like etoposide enhances cancer cell death. DNA damage sensitizes cells to activated Bid, a protein crucial for this synergistic apoptosis, revealing a new therapeutic strategy.
Area of Science:
- Oncology
- Molecular Biology
- Cell Death Research
Background:
- TRAIL (tumor necrosis factor-related apoptosis-inducing ligand) induces apoptosis selectively in tumors.
- Many tumor cells exhibit resistance to TRAIL-induced apoptosis alone.
- Co-treatment with DNA-damaging agents can sensitize resistant tumor cells to TRAIL.
Purpose of the Study:
- To elucidate the molecular mechanism behind the synergistic apoptosis induced by TRAIL and DNA-damaging agents in human mesothelioma cells.
- To investigate the role of Bid protein activation in TRAIL-etoposide mediated apoptotic synergy.
- To determine the causal relationship between caspase 8 cleavage and the apoptotic cascade in this synergistic effect.
Main Methods:
- Utilized human mesothelioma cell lines, known for therapeutic resistance.
- Investigated the role of Bid protein activation in response to TRAIL ligation and DNA damage.
- Analyzed caspase 8 cleavage patterns during combined TRAIL and etoposide treatment.
Main Results:
- Bid protein is essential for the synergistic apoptotic effect of TRAIL and etoposide.
- DNA damage primes cells to undergo apoptosis induced by sublethal levels of activated Bid.
- Extensive caspase 8 cleavage is a downstream consequence, not the cause, of the Bid-activated apoptotic cascade.
Conclusions:
- TRAIL-etoposide apoptotic synergy occurs because DNA damage enhances cellular sensitivity to TRAIL-activated Bid.
- This mechanism highlights how combining proapoptotic signals can overcome tumor refractoriness.
- The findings suggest a potential therapeutic strategy for treating resistant cancers through combined signaling pathways.
Related Concept Videos
The Intrinsic Apoptotic Pathway
The Extrinsic Apoptotic Pathway
Apoptosis
Cellular Injury V: Apoptosis and Autophagy
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
NF-κB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...

